Related Experiment Video
Updated: Jul 29, 2026
14:39
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
Inhaled hyperosmolar agents for bronchiectasis.
1Dept of Respiratory Medicine, Hillingdon Hospital, Pield Heath Road, Uxbridge, Middlesex, UK, UB8 3NN.
The Cochrane Database of Systematic Reviews
|March 1, 2002
Summary
Inhaled dry powder mannitol effectively doubled tracheobronchial clearance in bronchiectasis patients. Further research is needed for hypertonic saline and long-term mannitol studies.
Area of Science:
- Respiratory Medicine
- Pulmonology
Background:
- Mucus retention is a key feature of bronchiectasis, leading to bacterial colonization and airway damage.
- Neutrophilic response and protease activity contribute to lung injury in bronchiectasis.
- Hypertonic saline and inhaled dry powder mannitol show potential for improving mucus clearance.
Purpose of the Study:
- To evaluate the efficacy of inhaled hyperosmolar substances for treating bronchiectasis.
Main Methods:
- Searched MEDLINE and Cochrane databases, contacted field experts.
- Included trials of hyperosmolar inhalation in non-cystic fibrosis bronchiectasis patients.
- Analyzed data from one identified crossover trial.
Main Results:
- A single-dose of inhaled dry powder mannitol doubled tracheobronchial clearance in central and intermediate lung regions.
- No significant side effects were reported with mannitol, though some patients required premedication for bronchospasm.
- No additional studies were identified in a follow-up search.
Conclusions:
- Inhaled dry powder mannitol enhances tracheobronchial clearance in bronchiectasis.
- Hypertonic saline has demonstrated benefits in other respiratory conditions.
- Long-term randomized controlled trials are required to assess mannitol and hypertonic saline efficacy with clinical endpoints in bronchiectasis.
Related Concept Videos
01:16Drugs Used in Upper Respiratory Disorders: Overview
Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
01:17Drugs Used in Lower Respiratory Disorders: Overview
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
01:23Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by anesthetizing...
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by anesthetizing...
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
01:26COPD: Management Using Bronchodilators and Corticosteroids
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
01:23Inhaled Medications
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...